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BACKGROUND: Statin is an anti-cholesterol drug that is widely prescribed throughout the world. Statins are mainly used to treat and prevent 
cardiovascular disease. Several studies have found the 
pleiotropic effect of statin. However, related effect of statin 
in kidney failure is still unclear. Ischemic-reperfusion 
(I/R) injury is a major cause of acute kidney failure. This 
study aims to determine the effect of simvastatin on kidney 
function and glomerular conditions by periodic acid-schiff 
staining in I/R injury.
METHODS: Eighteen male Swiss mice were grouped 
into sham operation group (GSO), I/R injury group 
(GIRI), and simvastatin group (GSIM). The GSO group 
was performed by sham operation and pretreatment of 
1% carboxymethylcellulose (CMC) for 3 days. The GIRI 
group was performed by I/R procedure and pretreatment of 
1% CMC for 3 days and the GSIM group was performed 
by I/R procedure  and  pretreatment  of  10  mg/kg  BW 
simvastatin for 3 days. Blood urea nitrogen (BUN) and 
creatinine serum were assessed to determine kidney 
function. Histopathological analysis of glomerulosclerosis 
was assessed by the extent of glomerular damage (sclerosis), 
capillary loops, and synechia. The data were analyzed 
by one-way ANOVA followed by post hoc Tukey’s test 
(p<0.05).
RESULTS: The creatinine and BUN levels in the GIRI 
group were the highest (0.97±0.48) compared with the other 
groups. The glomerulosclerosis index in the GSO group was 
0.75±0.56, the GIRI group was 3.55±0.61, and the GSIM 
group was 2.08±1.37. There was a significant difference in 
the glomerulosclerosis index between the GSO and GIRI 
groups, but there was no significant difference between 
the GIRI and GSIM groups. These differences include the 
formation of sclerosis in the glomerulus, capillary loop, and 
synechiae.
CONCLUSION: Simvastatin improves kidney function 
and glomerulosclerosis in I/R injury.
KEYWORDS: ischemic-reperfusion injury, simvastatin, 
glomerulosclerosis
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Abstract
Introduction
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors is an anti-cholesterol drug that 
is widely prescribed throughout the world. Statins used to 
treat and prevent cardiovascular diseases, such as coronary 
heart diseases. This drug can decrease cholesterol synthesis 
and  increase  the number  of  low-density  lipoproteins 
(LDL) receptors,  thereby  speeding  up  the  cleansing 
of  cholesterol from circulation.(1,2) Statins work by 
inhibiting the enzyme HMG-CoA reductase, so blocking 
the mevalonate pathway includes inhibition of cholesterol 
biosynthesis and isoprenoid metabolites such as farnesyl-
diphosphate (FPP) and geranylgeranyl pyrophosphate 
(GGPP).(1,3,4)
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 Many studies have found good effects of statin in 
various conditions. Not only limited to cardiovascular 
disease but also in infectious diseases, neurological 
disorders, and tumors. Statins are also have been reported 
to have antioxidant and anti-inflammatory effects. This 
condition makes the statin therapy does not only limited to 
cardiovascular diseases, but also to the condition or disease 
that have a direct impact on dyslipidemia, as it does in the 
condition of kidney failure.(1,2)
 Kidney failure is a condition where there is a failure 
on kidney function. This condition can occur both in acute 
conditions (acute kidney injury/AKI) or chronic (chronic 
kidney disease/CKD). The research about the effects of 
statin on kidney failure is quite a lot with varying results. 
Previous research found that simvastatin had a remedial 
effect on creatinine, histopathological conditions and 
expression of several proteins such as α-smooth muscle 
actin (α-SMA), platelet-derived growth factor receptor beta 
(PDGF-Rβ), monocyte chemoattractant protein-1 (MCP-
1), intracellular adhesion molecule-1 (ICAM-1), nephrin, 
and podocin on mice with the 5/6 subtotal nephrectomy 
procedure.(5) Similar results were also found in research 
using the sepsis-induced AKI model.(6) In patients who will 
undergo surgery (abdomen, cardiac, thoracic and vascular), 
statins therapy can actually reduce the risk of postoperative 
AKI.(7)
 However, other studies have found that statins are not 
proven to affects kidney function, although it can prevent 
heart attack and stroke.(8) The use of high-dose statins 
(≥40 mg simvastatin, ≥20 mg atorvastatin, and ≥10 mg 
rosuvastatin) are also associated with increased risk of AKI. 
The administration 150 mg/kg/d for 7 days atorvastatin also 
reported has a nephrotoxic effect in the I/R injury.(9,10)
 I/R injury is the main cause of AKI. This injury can 
make a temporary decrease in blood flow in the kidneys and 
changes in renal cellular and vascular reactivity, so it may 
cause inflammation, cell death, and AKI.(11) Based on a 
meta-analysis the incidence of AKI is 21.6% in adults and 
33.7% in children, with a mortality rate of 23.9% (adults) 
and 13.8% (children).(12) Other studies mention the degree 
of mortality is between 25-80%, depending on the cause and 
clinical condition of the patient.(13) This condition is also 
associated with high health costs due to prolonged periods 
of hospitalization, increased examination costs and long-
term complications that can occur. The result can be even 
worse in developing countries compared with developed 
countries.(14)
 Based on the data above, it is known that there is 
still controversy on the effects of statin towards kidney 
conditions. For this reason, research needs to be done 
to determine the effect of statins on kidney conditions in 
animal models with AKI conditions.
Methods
Animals
Eighteen male Swiss mice (3-4 months, weight 30-40 g) 
were used in this study. Animals were kept in a standard room 
for animal studies (temperature 23±2°C and 12 h dark-light 
cycle). All animals got standard feed and ad libitum access 
to tap water. All the animal experiments were performed 
under protocol from The Ethics Committe for Research 
Faculty of Medicine Universitas Udayana/Sanglah Central 
General Hospital No: 2458/UN14.2.2.VII.14/LP/2019.
I/R Injury Model of AKI and Experimental Designs
Eighteen male Swiss mice were randomly and equally 
divided into 3 treatment groups: sham operation (GSO, n= 
6) as negative control, I/R injury (GIRI, n = 6) as positive 
control, and simvastatin (GSIM, n = 6). For GSIM group, 
mice was given pretreatment of 10 mg/kg BW simvastatin 
(Sigma-Aldrich, Science Park Road, Singapore) for 3 days 
before I/R procedure based on the previous protocol.(12) 
Simvastatin was dissolved in 1% carboxymethylcellulose 
(CMC) solution (Sigma-Aldrich, St Louis, MA, USA), 
then was given to the mice 1x/day by oral gavage. The dose 
of simvastatin in this study based on the median dose of 
the previous study.(5) The GSO group received 1% CMC 
solution and sham operation. The GIRI group received 
1% CMC solution and I/R procedure. I/R procedure was 
performed as follows, incisions were made at both the 
lumbar (flank) regions. After renal pedicles were exposed, 
both renal pedicles were clamped using Dieffenbach 
bulldog clamps (RZ Medizintechnik, Tuttlingen, Germany) 
for 30 min to induce ischemia. Then the clamps were 
removed to induce reperfusion. The incision sites were 
sutured and the mice were left conscious. The I/R procedure 
was performed after anesthetized with a combination of 90 
mg/kg BW ketamine and 10 mg/kb BW xylazine through 
intraperitoneal injection.(15) 
Biochemistry Analysis and Body Weight Determinations
Blood samples were collected from the retroorbital vein 
for the determination of blood urea nitrogen (BUN) and 
creatinine serum (DiaSys, Holzheim, Germany).  About 0.5-
1 mL blood was centrifuged at a speed of 10,000 rpm for 
10 min. Serum was obtained and stored at -20°C for further 
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analyses. For BUN examination, blood was reacted with 
Tris, 2-oxoglutarate, adenosine diphosphate (ADP), urease, 
glutamate dehydrogenase (GLDH), nicotinamide adenine 
dinucleotide hydride (NADH) for 1 min. The reaction was 
measured using a spectrophotometer at 340 nm wavelength. 
Then urea concentration and BUN value were calculated. 
For creatinine examination, blood was reacted with sodium 
hydroxide and picric acid 1 min. The reaction was measured 
using a spectrophotometer at 492 nm wavelength. Then 
creatinine concentration was calculated. Changes in the 
body weight of each group were determined during the 
acclimatization period until the end of the study.  
Histological Preparation and Assessments of Glomerulo-
sclerosis in Periodic Acid-Schiff (PAS) Staining
One day after I/R procedure mice were euthanized by 300 
mg/kg BW intraperitoneal injection of ketamine. Then the 
kidney was excised, cleaned carefully and fixed in 10% 
buffered paraformaldehyde and embedded in paraffin 
for histological processing sections. For histopathology 
analysis, block paraffin was cut (4 µm), then stained with 
PAS. Images were taken at 400× magnifications under a 
light microscope (Olympus, Tokyo, Japan).
 Histopathological analysis of glomerulosclerosis 
scores was assessed by the extent of glomerular damage 
(sclerosis), capillary loops, and synechia. Ten fields of 
view glomerulus will be examined and glomerulosclerosis 
scores classified from 0 to 4 (0 = normal glomeruli, 1 = area 
of sclerosis <25%, 2 = area of sclerosis 25-50%, 3 = area 
sclerosis >50-75%, 4 = area of sclerosis >75%).(5) The 
morphological measurement was performed blindly by 2 
observers. To avoid bias between observers, we performed 
Results
Characteristics of Animals
All animals were survived until the end of the study. 
During the acclimatization period, the body weight of the 
mice on treatment groups appeared stable (A1-A7). There 
was a slight increase in body weight at the beginning of 
the treatment (D2-D4), but there was a decrease in body 
weight at the end of the treatment (D5), as shown in Figure 
1. Based on the statistical analysis there was no significant 
difference in the mean bodyweight of the experimental 
group at the beginning of the treatment (D1) and the end 
of the treatment (D5). The mean body weight D1 in the 
GSO group = 32.67±1.36, GIRI = 32.3±1.51, GSIM = 
33.33±1.21; p=0.55, while the mean body weight of D5 
in the GSO group = 32±1.26, GIRI = 1.17±1.6, GSIM = 
31.83±1.16; p=0.54.
Biochemical Analysis
Based on the results we found that creatinine levels in the 
GIRI group were the highest (0.97±0.48) compared with 
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Figure 1. Body weight on treatment groups. 
GSO: sham operation; GIRI: I/R injury; 
GSIM: 10 mg/kg BW simvastatin + I/R injury; 
A: acclimatization day, D: treatment day.
a discussion to equalize the perception before starting the 
assessment.
Statistical Analyses
Data were analyzed using Statistical Package for the Social 
Sciences (SPSS) software version 20.0 (IBM Corporation, 
New York, USA). Data were expressed as mean±SEM and 
analyzed by one-way ANOVA followed by post hoc Tukey’s 
test. Statistical significance was set at p<0.05. 
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Figure 2. Creatinine serum levels in the treatment groups. 
GSO: sham operation; GIRI: I/R injury; GSIM: 10 mg/kg BW 
simvastatin + I/R injury. Tested with one way ANOVA, p=0.058.
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Figure 3. BUN levels in the treatment groups. GSO: sham 
operation; GIRI: I/R injury; GSIM: 10 mg/kg BW simvastatin + 
I/R injury. Tested with one way ANOVA, p=0.058
the GSO group (0.51±0.12) and GSIM group (0.8±0.17) 
(Figure 2). The BUN levels in the GIRI group (36±22.17) 
were also the highest compared with GSO (23.55±5.53) and 
GSIM (18.59±5.0) (Figure 3). However, statistical analysis 
showed that there were no significant differences between 
treatment groups p>0.05.
Glomerulosclerosis Index Analysis
The glomerular histopathology of the GSO group showed 
normal glomerulus without synechia, capillary loops still 
open and no sclerosis. This was different from the GIRI 
group. The glomerulus was very sclerotic, there was an 
attachment to the Bowman's capsule and all capillaries 
loop were closed. The absorption of red color was also very 
strong  compared  to  the  GSO  group.  In  the  GSIM 
group, the contour of glomerular was still clearly observed 
and there  was  no  attachment  to  the  Bowman's  capsule. 
Some  capillary  loops  were  still  open,  as  shown  in 
Figure 4. 
 The mean of glomerulosclerosis index in each group 
was: GSO (0.75±0.56), GIRI (3.55±0.61), and GSIM 
(2.08±1.37) (Figure 5). There was significant difference 
between the GSO and GIRI groups (p=0.007), but there 
was no significant difference between the GIRI and GSIM 
groups. Glomerulosclerosis index in the GSIM group 
showed a decrease, but not statistically significant. These 
results indicated that damage occurred in the glomerulus 
was very minimal in the group without AKI (GSO group), 
compared with the group with AKI (GIRI group), shown 
by >4 times increase of the glomerulosclerosis index in the 
GIRI group. In the GSIM group, glomerular damage was 
also occurred due to the I/R procedure but to a lesser degree 
than the GIRI group. 
Discussion
In this study, BUN and creatinine serum levels were 
increased one day after the I/R procedure. These results are 
consistent with the previous studies showing the BUN and 
serum creatinine levels are increased at 2, 4, and 6 h post-
ischemia and peak elevations at 24 h post-ischemia.(16) 
 Increased BUN and creatinine indicated damage 
to the filtration process on the kidneys. Filtration is an 
important process associated with increased blood levels of 
BUN and creatinine. The structure involved in the process 
is glomerulus. The glomerulus is a structure with multiple 
interactions, namely endothelial cells, mesangial cells and 
epithelial cells which together form a filtration webbing 
(capillary loops).(17) Fibrosis that occurs in the glomerulus 
is known as glomerulosclerosis. Glomerulosclerosis is 
caused by the accumulation of collagen in the extracellular 
matrix. Glomerular injury can be the basis for this 
condition. Glomerular injury causes endothelial dysfunction 
and hemodynamic changes. The initial recruitment of 
neutrophils and immune response can cause by the activation 
of the renin-angiotensin-aldosterone system (RAAS). 
The presence of transforming growth factor-β (TGF-β), 
activation of connective tissue growth factor (CTGF), 
plasminogen activator inhibitor-1 (PAI-1) and nuclear factor 
ĸB (NFĸB) are factors that also exacerbate the immune 
response.(18) In this study, glomerulosclerosis has occurred 
with varying degrees. Pretreatment of simvastatin can 
reduce the degree of sclerosis on the GSIM group because 
of its renoprotection action. The renoprotective effect of 
statins has been confirmed by other studies. This effect may 
be obtained through their anti-inflammatory and antioxidant 
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Figure 4. Kideny glomerulus on PAS staining. Yellow arrow: normal glomeruli; White arrow: sclerotic glomeruli. White bar: 50 mm.
CBA
Figure 5. Glomerulosclerosis index in the treatment groups. 
GSO: sham operation; GIRI: I/R injury; GSIM: 10 mg/kg BW 
simvastatin + I/R injury. Tested with one way ANOVA, p=0.01 
GSO vs. GIRI)
actions. On the kidney, statin can increase the filtration rate 
of the glomerulus, tubular function and reducing markers 
of oxidative injury. Through these actions, the condition of 
the kidney will gradually improve.(19) Other studies have 
found that the protective effect of statin caused by inhibition 
in the mevalonate pathway, independent of its lipid-lowering 
action.(20)
 An increasing dose of simvastatin was reported to 
have a renoprotective effect. At a dose of 5.2 mg/kg BW, 
10.4 mg/kg BW and 20.8 mg/kg BW, simvastatin was 
reported to improve glomerulosclerosis, tubular injury 
and interstitial fibrosis in the 5/6 subtotal nephrectomy 
model significantly.5 Simvastatin has also been reported to 
improve the severity of proteinuria, BUN and histological 
changes at doses of 1 mg/kg, 10 mg/kg and 25 mg/kg in a 
dose-dependent manner.(21) On a clinical trial, atorvastatin 
also demonstrated improve kidney function over time in a 
dose‐dependent manner.(22)
 Weakness in this study is the limited number of the 
treatment group. The researchers only used one dose of 
the drug, so the effect that occurs in increasing doses of 
simvastatin not yet known. This research is also still limited 
to histopathological studies and not yet reached studies at 
the level of molecular biology. This causes the data is still 
limited. Therefore, further research is needed to determine 
the effective dose of simvastatin in this model, as well as 
research related to the effects of drugs from the molecular 
aspect. 
Conclusion
The result of this study shows that simvastatin improves 
kidney function and glomerulosclerosis in I/R injury.
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